{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T06:15:24Z","timestamp":1761200124179,"version":"build-2065373602"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003569","name":"the Ministry of Food and Drug Safety","doi-asserted-by":"crossref","award":["RS-2023-00216446"],"award-info":[{"award-number":["RS-2023-00216446"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Tandem autologous stem cell transplantation (tASCT) is a viable option for high-risk multiple myeloma (MM) patients. Minimal residual disease (MRD), a real-time surrogate marker of disease burden, serves as a valuable measure of treatment response. This study evaluated the impact of tASCT on MRD dynamics in MM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed data from a multicenter registry of 28 patients who underwent tASCT as frontline treatment between January 2019 and October 2024. Eligibility criteria included undergoing two ASCTs within one year, having MRD positivity before tASCT, and completing follow-up MRD assessment. Patients were stratified into two groups: extensive MRD clearance (\u2265\u200950% reduction,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918) and modest MRD clearance (&lt;\u200950% reduction,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Across the entire cohort, mean MRD decreased from 0.111% pre-tASCT to 0.056% post-tASCT. Three patients achieved MRD negativity, 20 had reductions without negativity, and five experienced increases. The extensive clearance group showed significant MRD reduction (0.152% to 0.017%) and longer progression-free survival (PFS: 37.7 vs. 16.3\u00a0months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013) compared with the modest clearance group, in which MRD increased (0.175% to 0.830%). Overall survival did not differ significantly.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>tASCT provides clinical benefit for MRD-positive MM patients, particularly those achieving significant MRD reduction. These findings support tASCT as a feasible approach for MRD-positive patients following initial ASCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s44313-025-00101-6","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T06:12:10Z","timestamp":1761199930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease: an explorative study"],"prefix":"10.1007","volume":"60","author":[{"given":"Sieun","family":"Oh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-4136","authenticated-orcid":false,"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hwan","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Woo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Ah","family":"Yahng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myungshin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1940-0392","authenticated-orcid":false,"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"101_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/nyas.13038","volume":"1364","author":"H Fairfield","year":"2016","unstructured":"Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016;1364:32\u201351.","journal-title":"Ann N Y Acad Sci"},{"key":"101_CR2","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691\u20135.","journal-title":"Blood"},{"key":"101_CR3","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1182\/blood-2015-04-638742","volume":"126","author":"J Martinez-Lopez","year":"2015","unstructured":"Martinez-Lopez J, Paiva B, Lopez-Anglada L, et al. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood. 2015;126:858\u201362.","journal-title":"Blood"},{"key":"101_CR4","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood.2021012319","volume":"138","author":"A Jimenez-Ubieto","year":"2021","unstructured":"Jimenez-Ubieto A, Paiva B, Puig N, et al. Validation of the International Myeloma Working Group standard response criteria in the PETHEMA\/GEM2012MENOS65 study: are these times of change? Blood. 2021;138:1901\u20135.","journal-title":"Blood"},{"key":"101_CR5","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","volume":"125","author":"B Paiva","year":"2015","unstructured":"Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059\u201368.","journal-title":"Blood"},{"key":"101_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s44313-025-00055-9","volume":"60","author":"SH Jung","year":"2025","unstructured":"Jung SH, Koh Y, Kim MK, et al. Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions. Blood Res. 2025;60:9.","journal-title":"Blood Res"},{"key":"101_CR7","first-page":"4100","volume":"109","author":"A Ahn","year":"2024","unstructured":"Ahn A, Park SS, Kim Y, et al. Minimal residual disease assessment in transplant-eligible patients with multiple myeloma: real-world applications of multiparametric flow cytometry-DURAClone (CAREMM-2104). Haematologica. 2024;109:4100\u20135.","journal-title":"Haematologica"},{"key":"101_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.2021011101","volume":"139","author":"M Cavo","year":"2022","unstructured":"Cavo M, San-Miguel J, Usmani SZ, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022;139:835\u201344.","journal-title":"Blood"},{"key":"101_CR9","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e890\u2013901.","journal-title":"Lancet Haematol"},{"key":"101_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","volume":"119","author":"B Paiva","year":"2012","unstructured":"Paiva B, Gutierrez NC, Rosinol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119:687\u201391.","journal-title":"Blood"},{"key":"101_CR11","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.21.02228","volume":"40","author":"RM de Tute","year":"2022","unstructured":"de Tute RM, Pawlyn C, Cairns DA, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022;40:2889\u2013900.","journal-title":"J Clin Oncol"},{"key":"101_CR12","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.bbmt.2017.01.076","volume":"23","author":"R Chakraborty","year":"2017","unstructured":"Chakraborty R, Muchtar E, Kumar SK, et al. Impact of post-transplant response and minimal residual disease on survival in myeloma with high-risk cytogenetics. Biol Blood Marrow Transplant. 2017;23:598\u2013605.","journal-title":"Biol Blood Marrow Transplant"},{"key":"101_CR13","volume":"5","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis. Treatment and Follow-up Hemasphere. 2021;5:e528.","journal-title":"Treatment and Follow-up Hemasphere"},{"key":"101_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V89.3.789","volume":"89","author":"B Barlogie","year":"1997","unstructured":"Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789\u201393.","journal-title":"Blood"},{"key":"101_CR15","doi-asserted-by":"publisher","first-page":"E195","DOI":"10.1002\/ajh.26530","volume":"97","author":"M Mohan","year":"2022","unstructured":"Mohan M, Gundarlapalli S, Szabo A, et al. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022;97:E195-8.","journal-title":"Am J Hematol"},{"key":"101_CR16","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.bbmt.2019.07.004","volume":"25","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Eikema DJ, Koster L, et al. Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25:2134\u201342.","journal-title":"Biol Blood Marrow Transplant"},{"key":"101_CR17","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"101_CR18","doi-asserted-by":"crossref","unstructured":"Park SS, Shin SH, Lee JY, Jeon YW, Yhang SA, Min CK. Prospective Comparative Study of Etoposide plus G-CSF versus G-CSF Alone, Followed by Risk-Adapted Plerixafor for Peripheral Blood Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma: CAtholic REsearch Network for Multiple Myeloma Study (CAREMM-2001). Cancers (Basel) 2023;15.","DOI":"10.20944\/preprints202308.1526.v1"},{"key":"101_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.4274\/dir.2023.232097","volume":"29","author":"SS Park","year":"2023","unstructured":"Park SS, Kwag D, Lee JY, et al. Prognostic value of low muscle mass at the 12(th) thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study. Diagn Interv Radiol. 2023;29:596\u2013608.","journal-title":"Diagn Interv Radiol"},{"issue":"55","key":"101_CR20","first-page":"e1","volume":"29","author":"Y Kim","year":"2023","unstructured":"Kim Y, Park SS, Jeon YW, et al. Response and Dynamics of Renal Function in Transplantation-Eligible Multiple Myeloma Patients Treated with a Novel Agent: The CAREMM-2201 Study. Transplant Cell Ther. 2023;29(55):e1\u20139.","journal-title":"Transplant Cell Ther"},{"key":"101_CR21","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D'Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"101_CR22","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"101_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12885-024-12077-0","volume":"24","author":"Y Tao","year":"2024","unstructured":"Tao Y, Jin S, Yang D, et al. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma. BMC Cancer. 2024;24:406.","journal-title":"BMC Cancer"},{"key":"101_CR24","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1200\/JCO.20.01814","volume":"39","author":"H Avet-Loiseau","year":"2021","unstructured":"Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39:1139\u201349.","journal-title":"J Clin Oncol"},{"key":"101_CR25","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38:784\u201392.","journal-title":"J Clin Oncol"},{"key":"101_CR26","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","volume":"4","author":"J Martinez-Lopez","year":"2020","unstructured":"Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4:3295\u2013301.","journal-title":"Blood Adv"},{"key":"101_CR27","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1200\/JCO.21.01045","volume":"39","author":"P Sonneveld","year":"2021","unstructured":"Sonneveld P, Dimopoulos MA, Beksac M, et al. Consolidation and maintenance in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39:3613\u201322.","journal-title":"J Clin Oncol"},{"key":"101_CR28","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","volume":"125","author":"AC Rawstron","year":"2015","unstructured":"Rawstron AC, Gregory WM, de Tute RM, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125:1932\u20135.","journal-title":"Blood"},{"key":"101_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood.2020008090","volume":"137","author":"J Corre","year":"2021","unstructured":"Corre J. Undetectable MRD can change the deal. Blood. 2021;137:5\u20136.","journal-title":"Blood"},{"key":"101_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37:589\u201397.","journal-title":"J Clin Oncol"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00101-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00101-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00101-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T06:12:15Z","timestamp":1761199935000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00101-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["101"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00101-6","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"type":"print","value":"2287-979X"},{"type":"electronic","value":"2288-0011"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}